文献速递神经免疫神经肌肉病

重症肌无力基因组研究揭示早发型与晚发型的不同免疫机制

Genomic Insights into Myasthenia Gravis Identify Distinct Immunological Mechanisms in Early and Late Onset Disease.
PubMed 文献 · Ann Neurol · 2021-08-04

本研究利用基因组学方法整合全基因组关联研究(GWAS)与细胞类型特异性信息,识别重症肌无力相关基因,并对313名健康人进行表达定量分析。结果发现早发型与Toll样受体4信号调控因子相关,晚发型则与T细胞调节因子CD28和CTLA4相关,且CTLA4附近两个因果变异导致其低表达。

要点

  • 早发型重症肌无力相关基因包括TNIP1、ORMDL3、GSDMB和TRAF3。
  • 晚发型重症肌无力与CD28和CTLA4基因关联,CTLA4低表达由因果变异介导。
  • 早发型与晚发型涉及不同免疫通路,对药物重定位和研发有启示。

核心结论

  • 早发型和晚发型重症肌无力由不同的免疫学通路驱动,早发型与Toll样受体4信号调控因子相关,晚发型与T细胞调节因子相关。

研究设计与样本

  • 研究采用新型基因组学方法,整合重症肌无力GWAS结果与细胞类型特异性信息(基因表达模式和启动子-增强子相互作用),并对313名健康人进行表达定量分析。

主要发现

  • 早发型重症肌无力相关基因包括TNIP1、ORMDL3、GSDMB和TRAF3,Toll样受体4信号调控因子在早发型疾病基因中富集(富集倍数=3.85,p=6.4×10-3)。
  • 晚发型重症肌无力独有T细胞调节因子CD28和CTLA4关联,并识别出CTLA4基因附近2个因果遗传变异(rs231770和rs231735;后验概率=0.98和0.91)。
  • 因果变异rs231735和rs231770分别与CTLA4低表达相关(rho=-0.66,p=1.28×10-38;rho=-0.52,p=7.01×10-22)。

关键数值与推荐

  • 早发型疾病基因中Toll样受体4信号调控因子富集(富集倍数=3.85,p=6.4×10-3)。
  • CTLA4基因附近因果变异rs231770和rs231735的后验概率分别为0.98和0.91。
  • rs231735与CTLA4表达负相关(rho=-0.66,p=1.28×10-38),rs231770与CTLA4表达负相关(rho=-0.52,p=7.01×10-22)。

临床怎么用

  • 研究识别的疾病相关基因为临床医生、科学家和制药行业提供了独特资源。
  • 早发型与晚发型重症肌无力的不同免疫通路对药物重定位机会和未来药物开发研究有重要启示。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to identify disease relevant genes and explore underlying immunological mechanisms that contribute to early and late onset forms of myasthenia gravis. METHODS: We used a novel genomic methodology to integrate genomewide association study (GWAS) findings in myasthenia gravis with cell-type specific information, such as gene expression patterns and promotor-enhancer interactions, in order to identify disease-relevant genes. Subsequently, we conducted additional genomic investigations, including an expression quantitative analysis of 313 healthy people to provide mechanistic insights. RESULTS: We identified several genes that were specifically linked to early onset myasthenia gravis including TNIP1, ORMDL3, GSDMB, and TRAF3. We showed that regulators of toll-like receptor 4 signaling were enriched among these early onset disease genes (fold enrichment = 3.85, p = 6.4 × 10-3 ). In contrast, T-cell regulators CD28 and CTLA4 were exclusively linked to late onset disease. We identified 2 causal genetic variants (rs231770 and rs231735; posterior probability = 0.98 and 0.91) near the CTLA4 gene. Subsequently, we demonstrated that these causal variants result in low expression of CTLA4 (rho = -0.66, p = 1.28 × 10-38 and rho = -0.52, p = 7.01 × 10-22 , for rs231735 and rs231770, respectively). INTERPRETATION: The disease-relevant genes identified in this study are a unique resource for many disciplines, including clinicians, scientists, and the pharmaceutical industry. The distinct immunological pathways linked to early and late onset myasthenia gravis carry important implications for drug repurposing opportunities and for future studies of drug development. ANN NEUROL 2021;90:455-463.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Handunnetthi L, Knezevic B, Kasela S, et al. Genomic Insights into Myasthenia Gravis Identify Distinct Immunological Mechanisms in Early and Late Onset Disease. Ann Neurol. 2021. PMID: 34279044. doi:10.1002/ana.26169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。